Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
05/13/2019 05/14/2019 05/15/2019 05/16/2019 05/17/2019 Date
137.2(c) 136.82(c) 136.91(c) 138.21(c) 138.61(c) Last
5 560 421 7 179 438 6 429 352 6 857 180 6 915 286 Volume
-1.33% -0.28% +0.07% +0.95% +0.29% Change
More quotes
Financials (USD)
Sales 2019 81 174 M
EBIT 2019 25 487 M
Net income 2019 19 737 M
Debt 2019 9 323 M
Yield 2019 2,71%
Sales 2020 84 655 M
EBIT 2020 27 898 M
Net income 2020 21 550 M
Finance 2020 5 580 M
Yield 2020 2,89%
P/E ratio 2019 19,50
P/E ratio 2020 17,72
EV / Sales2019 4,65x
EV / Sales2020 4,28x
Capitalization 368 B
More Financials
Company
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (49.9%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses,... 
Sector
Pharmaceuticals
Calendar
05/24Ex-dividend day for
More about the company
Surperformance© ratings of Johnson & Johnson
Trading Rating : Investor Rating :
More Ratings
Latest news on JOHNSON & JOHNSON
05:43aFBI probes J&J, Siemens, GE, Philips in Brazil graft case bribery
AQ
05/19Modi’s jobs deficit - J&J’s largest India plant idle three years ..
RE
05/18JOHNSON & JOHNSON : J&J unveils top pipeline prospects, with main focus on cance..
AQ
05/17EXCLUSIVE : FBI targets Johnson & Johnson, Siemens, GE, Philips in Brazil graft ..
RE
05/17JOHNSON & JOHNSON : to Participate in Bernstein's 35th Annual Strategic Decision..
PR
05/17“MY LIFE'S MISSION IS FINDING : Meet the Lead Scientist on a Promising Fe..
PU
05/15JOHNSON & JOHNSON : Outlines Strategy to Deliver Above-Market Growth at 2019 Pha..
PR
05/15JOHNSON & JOHNSON : German Merck shows new data backing BTK drug evobrutinib in ..
AQ
05/14JOHNSON & JOHNSON : Janssen Demonstrates Strong Commitment to Inflammatory Bowel..
PU
05/13JOHNSON & JOHNSON : Janssen Pharmaceutical - New Study Finds Chronic Kidney Dise..
AQ
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Sector news : Pharmaceuticals - NEC
05/17ABBVIE : halts enrollment after brain cancer trial misses goal, shares fall
RE
05/17ABBVIE : Glioblastoma Drug Misses Primary Endpoint
DJ
05/16MIRATI THERAPEUTICS : Shares Jump 17% on Rival Amgen's Progress on Potential Can..
DJ
05/16PFIZER : FDA Approves Pfizer's Fragmin for Use as a Pediatric Anticoagulant
DJ
05/16CELGENE : Says EC Approves two Triplet Regimens for Multiple Myeloma
DJ
More sector news : Pharmaceuticals - NEC
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 148 $
Spread / Average Target 6,7%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Charles O. Prince Independent Director
William David Perez Independent Director
Anne M. Mulcahy Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON7.41%368 017
PFIZER-4.99%230 570
ROCHE HOLDING LTD.9.35%227 259
NOVARTIS13.20%210 489
MERCK AND COMPANY3.02%202 676
ABBVIE-13.81%117 468